JOHNSON & JOHNSON — Director's Dealing 2004

Jun 4, 2004

SEC Form 4/A — Form 4/A

Issuer: BARRIER THERAPEUTICS INC (BTRX)
CIK: 0001173657
Period of Report: 2004-04-28

Reporting Person: JOHNSON & JOHNSON (10% Owner)
Reporting Person: Janssen Pharmaceutica Products, L.P. (10% Owner)
Reporting Person: Johnson & Johnson Consumer Companies, Inc. (10% Owner)
Reporting Person: JOHNSON & JOHNSON DEVELOPMENT CORP ET AL (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2004-04-28	Common Stock	C	4448076	—	Acquired	4448076	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2004-04-28	Series A Convertible Preferred Stock	$	C	8333333	Disposed		Common Stock ()	Indirect
2004-04-28	Series B Convertible Preferred Stock	$	C	50000	Disposed		Common Stock ()	Indirect
2004-04-28	Series C Convertible Preferred Stock	$	C	512820	Disposed		Common Stock ()	Indirect

Footnotes

F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by the following subsidiaries of the Reporting Person: Johnson & Johnson Consumer Companies, Inc. (1,016,666 shares of Common Stock); Janssen Pharmaceutica Products, L.P. (3,150,000 shares Common Stock); Johnson & Johnson Development Corporation (281,410 shares Common Stock).

F2: Automatic conversion of each share of Series A Convertible Preferred Stock, owned by Johnson & Johnson Consumer Companies, Inc. and Janssen Pharmaceutica Products, L.P., into .5 shares of Common Stock upon the effectiveness of the Issuer's initial public offering.

F3: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by the following subsidiaries of the Reporting Person: Johnson & Johnson Consumer Companies, Inc.; Janssen Pharmaceutica Products, L.P.

F4: Automatic conversion of each share of Series B Convertible Preferred Stock, owned by Johnson & Johnson Development Corporation , into .5 shares of Common Stock upon the effectiveness of the Issuer's initial public offering.

F5: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by the following subsidiary of the Reporting Person: Johnson & Johnson Development Corporation.

F6: Automatic conversion of each share of Series C Convertible Preferred Stock, owned by Johnson & Johnson Development Corporation, into .5 shares of Common Stock upon the effectiveness of the Issuer's initial public offering.

F7: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by the following subsidiary of the Reporting Person: Johnson & Johnson Development Corporation.

F8: The reported transactions are not new or revised but are being reported again to gain access to the system to file this amendment, the sole purpose of which is to add Johnson & Johnson Development Corporation, Janssen Pharmaceutica Products, L.P. and Johnson & Johnson Consumer Companies, Inc. as joint filers.